Clinical Trial Detail

NCT ID NCT03471663
Title A First-in-Human Study of D-0502 Alone and in Combination With Palbociclib in Women With Advanced or Metastatic ER-Positive and HER2-Negative Breast Cancer
Recruitment Recruiting
Gender female
Phase Phase I
Variant Requirements yes
Sponsors InventisBio Inc.
Indications

Her2-receptor negative breast cancer

Therapies

D-0502 + Palbociclib

D-0502

Age Groups: adult senior

Additional content available in CKB BOOST